Results 31 to 40 of about 86,566 (299)

Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models [PDF]

open access: yes, 2016
To understand the persistence of latently HIV-1 infected cells in virally suppressed infected patients, a number of in vitro models of HIV latency have been developed.
Bonczkowski, Pawel   +7 more
core   +1 more source

Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes

open access: yesRetrovirology, 2009
Background Integrase inhibitors are currently being incorporated into highly active antiretroviral therapy (HAART). Due to high HIV variability, integrase inhibitor efficacy must be evaluated against a range of integrase enzymes from different subtypes ...
Kuhl Björn D   +7 more
doaj   +1 more source

Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013–2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors [PDF]

open access: yes, 2017
Objectives To characterize the prevalence of transmitted drug resistance mutations (TDRMs) by plasma analysis of 750 patients at the time of HIV diagnosis from January 1, 2013 to November 16, 2016 in the Veneto region (Italy), where all drugs included in
Alvarez, M   +18 more
core   +1 more source

Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways

open access: yesDrug Metabolism And Disposition, 2019
Preliminary analysis of ongoing birth surveillance study identified evidence of potential increased risk for neural tube defects (NTDs) in newborns associated with exposure to dolutegravir at the time of conception. Folate deficiency is a common cause of
M. Zamek-Gliszczynski   +8 more
semanticscholar   +1 more source

Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART

open access: yesInfectious Disease Reports, 2022
HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance.
Helene Mens   +3 more
doaj   +1 more source

Update on HIV integrase inhibitors for the treatment of HIV-1 infection

open access: yesFuture Virology, 2019
It has been over 30 years since the first antiretroviral agent was approved for treatment of HIV-1 infection and its impact on morbidity and mortality has been dramatic.
Blake Max
semanticscholar   +1 more source

Adaptive HIV-1 evolutionary trajectories are constrained by protein stability [PDF]

open access: yes, 2017
Despite the use of combination antiretroviral drugs for the treatment of HIV-1 infection, the emergence of drug resistance remains a problem. Resistance may be conferred either by a single mutation or a concerted set of mutations.
Kandathil, Shaun M.   +3 more
core   +2 more sources

Absence of Resistance Mutations in the Integrase Coding Region among ART-Experienced Patients in the Republic of the Congo

open access: yesMicroorganisms, 2021
Background: HIV infects around one hundred thousand patients in the Republic of the Congo. Approximately 25% of them receive an antiretroviral treatment; current first-line regimens include two NRTIs and one NNRTI, reverse transcriptase inhibitors ...
Ferdinand Emaniel Brel Got   +7 more
doaj   +1 more source

Dolutegravir-based regimen maintains virological success in a patient with archived mutations to integrase inhibitors [PDF]

open access: yes, 2017
no abstract ...
Falasca, Francesca   +3 more
core   +1 more source

Resistance to novel drug classes [PDF]

open access: yes, 2009
Understanding the mechanisms that underlie resistance development to novel drugs is essential to a better clinical management of resistant viruses and to prevent further resistance development and spread. RECENT FINDINGS: Integrase inhibitors and CCR5
Calvez, V.   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy